# Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer

> **NCT00636441** · PHASE2 · TERMINATED · sponsor: **Duke University** · enrollment: 56 (actual)

## Conditions studied

- Early-Stage Breast Cancer

## Interventions

- **DRUG:** Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)

## Key facts

- **NCT ID:** NCT00636441
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 56 (ACTUAL)
- **Why stopped:** Study terminated due to reproducibility issues with genomics prediction model
- **Last updated:** 2015-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00636441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00636441, "Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00636441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*